融资方面，海思科当日融资买入1489.42万元。当前融资余额6837.94万元，占流通市值的0.13%，融资 余额超过近一年80%分位水平，处于高位。 2月3日，海思科跌5.47%，成交额4.30亿元。两融数据显示，当日海思科获融资买入额1489.42万元，融 资偿还1357.27万元，融资净买入132.15万元。截至2月3日，海思科融资融券余额合计7517.19万元。 融券方面，海思科2月3日融券偿还900.00股，融券卖出1300.00股，按当日收盘价计算，卖出金额6.17万 元；融券余量14.30万股，融券余额679.25万元，低于近一年20%分位水平，处于低位。 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 截至9月30日，海思科股东户数1.29万，较上期增加12. ...

数据显示，摩根基金旗下1只基金重仓海思科。摩根医疗健康股票A（001766）四季度持有股数53.88万 股，占基金净值比例为6.04%，位居第七大重仓股。根据测算，今日浮亏损失约157.32万元。 2月3日，海思科跌5.81%，截至发稿，报47.33元/股，成交7384.70万元，换手率0.31%，总市值530.06亿 元。 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 从基金十大重仓股角度 截至发稿，叶敏累计任职时间3年193天，现任基金资产总规模16.45亿元，任职期间最佳基金回报 48.26%， 任职期间最差基金回报2.38%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如 ...

Core Viewpoint - The stock price of Haishike has experienced a decline, with a current trading price of 50.70 yuan per share, reflecting a year-to-date drop of 1.21% and a 5-day drop of 5.62% [1] Financial Performance - For the period from January to September 2025, Haishike achieved an operating revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2] - Cumulatively, Haishike has distributed a total of 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders of Haishike increased by 12.87% to 12,900, with an average of 37,342 circulating shares per person, down by 11.40% [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3] Market Activity - As of January 22, Haishike's stock saw a trading volume of 51.53 million yuan, with a turnover rate of 0.21% and a total market capitalization of 56.78 billion yuan [1] - The main capital flow indicated a net outflow of 6.3653 million yuan, with significant selling activity observed [1]

Group 1 - The core viewpoint of the news is that 海思科 has shown a mixed performance in stock price and financial results, with a notable increase in stock price recently but a decline in net profit year-on-year [1][2]. Group 2 - As of January 9, 海思科's stock price increased by 2.09% to 56.15 CNY per share, with a total market capitalization of 628.83 billion CNY [1]. - The company has seen a year-to-date stock price increase of 9.41%, with a 9.41% rise over the last five trading days, a 3.98% decline over the last 20 days, and an 8.13% increase over the last 60 days [1]. - For the period from January to September 2025, 海思科 reported a revenue of 3.3 billion CNY, representing a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million CNY [2]. - The company has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed in the last three years [3]. - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, while the average circulating shares per person decreased by 11.40% to 37,342 shares [2][3].

Group 1 - The core viewpoint of the news is that 海思科 (Haisco) has shown a slight increase in stock price, reaching 51.14 yuan per share, with a total market capitalization of 57.273 billion yuan as of December 31 [1] - 海思科's main business involves the research, development, production, and sales of chemical pharmaceuticals, with revenue composition as follows: anesthetic products 39.81%, cooperative product-related income 23.59%, other indications 17.02%, parenteral nutrition 10.32%, antiemetics for tumors 8.15%, and other (supplementary) 0.86% [1] Group 2 - 中欧医疗健康混合A (China Europe Medical Health Mixed A) fund has increased its holdings in 海思科 by 121,200 shares, bringing its total to 21,397,500 shares, which accounts for 4.44% of the circulating shares [2] - The fund has achieved a year-to-date return of 13.6% and a one-year return of 11.58%, ranking 5,297 out of 8,085 in its category [2] Group 3 - The fund manager of 中欧医疗健康混合A is 葛兰 (Gelan) and 赵磊 (Zhao Lei), with total fund assets of 435.44 billion yuan and 329.54 billion yuan respectively [3] - 葛兰 has a tenure of 10 years and 340 days, with the best fund return of 97.86% and the worst return of -35.13% during her tenure [3] Group 4 - 中欧医疗健康混合A has 海思科 as its tenth largest holding, representing 3.47% of the fund's net value, with a floating profit of approximately 11.1267 million yuan [4]

12月29日，海思科跌2.16%，成交额1.79亿元。两融数据显示，当日海思科获融资买入额902.50万元， 融资偿还695.61万元，融资净买入206.89万元。截至12月29日，海思科融资融券余额合计5327.35万元。 截至9月30日，海思科股东户数1.29万，较上期增加12.87%；人均流通股37342股，较上期减少11.40%。 2025年1月-9月，海思科实现营业收入33.00亿元，同比增长19.95%；归母净利润2.95亿元，同比减少 22.66%。 分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年9月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2139.75万股，相比上期增加12.12万股。香港中央结算有限公司位居第六大流通股 东，持股1806.01万股，相比上期增加988.04万股。工银前沿医疗股票A（001717）位居第七大流通股 东，持股1560.01万股，相比上期增加50.00万股。汇添富创新医药混合A（006113）位居第八大流通股 东，持股1305.57万股，相比上期增加62 ...

海思科今年以来股价涨59.34%，近5个交易日跌3.93%，近20日跌6.48%，近60日跌4.02%。 12月19日，海思科盘中上涨2.04%，截至09:54，报52.55元/股，成交1620.64万元，换手率0.06%，总市 值588.52亿元。 资金流向方面，主力资金净流出43.16万元，大单买入150.72万元，占比9.30%，卖出193.89万元，占比 11.96%。 截至9月30日，海思科股东户数1.29万，较上期增加12.87%；人均流通股37342股，较上期减少11.40%。 2025年1月-9月，海思科实现营业收入33.00亿元，同比增长19.95%；归母净利润2.95亿元，同比减少 22.66%。 分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年9月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2139.75万股，相比上期增加12.12万股。香港中央结算有限公司位居第六大流通股 东，持股1806.01万股，相比上期增加988.04万股。工银前沿医疗股票A（001717）位居第七大流通股 ...

Core Insights - The stock price of Haisco fell by 2.02% on November 25, trading at 57.81 CNY per share with a market capitalization of 64.742 billion CNY [1] - Haisco's stock has increased by 75.29% year-to-date, with a 5-day increase of 5.70% and a 20-day increase of 11.77% [1] - The company reported a revenue of 3.3 billion CNY for the first nine months of 2025, a year-on-year increase of 19.95%, while net profit decreased by 22.66% to 295 million CNY [2] Financial Performance - Haisco's main business revenue composition includes: anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1] - Cumulative cash dividends since A-share listing amount to 3.673 billion CNY, with 687 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Haisco had 12,900 shareholders, an increase of 12.87% from the previous period [2] - The top ten circulating shareholders include various funds, with notable increases in holdings from several institutional investors [3]

Core Viewpoint - The stock of Haishike has shown significant performance with a year-to-date increase of 69.22%, despite a recent decline over the past 60 days [1][2]. Group 1: Stock Performance - As of November 19, Haishike's stock price reached 55.81 CNY per share, with a market capitalization of 62.503 billion CNY [1]. - The stock has experienced a 2.05% increase during the trading session on November 19, with a trading volume of 55.9157 million CNY [1]. - Over the last five trading days, the stock has risen by 2.78%, and over the last 20 days, it has increased by 7.33%, while it has decreased by 5.09% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Haishike reported a revenue of 3.3 billion CNY, reflecting a year-on-year growth of 19.95% [2]. - The net profit attributable to shareholders for the same period was 295 million CNY, which represents a year-on-year decrease of 22.66% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Haishike increased to 12,900, marking a 12.87% rise from the previous period [2]. - The average number of circulating shares per shareholder decreased by 11.40% to 37,342 shares [2]. - The company has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the last three years [3]. Group 4: Institutional Holdings - As of September 30, 2025, notable institutional shareholders include China Europe Medical Health Mixed A, holding 21.3975 million shares, and Hong Kong Central Clearing Limited, holding 18.0601 million shares, both showing increases in their holdings [3]. - Other significant institutional shareholders include ICBC Frontier Medical Stock A and Huatai-PineBridge Innovation Medical Mixed A, with varying changes in their shareholdings [3].

Core Viewpoint - The stock of Haishike has shown a significant increase of 64.01% year-to-date, despite a recent decline of 2.96% over the past five trading days, indicating volatility in its performance [1][2]. Financial Performance - For the period from January to September 2025, Haishike achieved a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haishike increased by 12.87% to 12,900, with an average of 37,342 circulating shares per shareholder, down by 11.40% [2]. - The top ten circulating shareholders include several institutional investors, with notable increases in holdings from entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3]. Stock Market Activity - On November 10, Haishike's stock price rose by 2.04% to 54.09 yuan per share, with a trading volume of 123 million yuan and a turnover rate of 0.48%. The total market capitalization reached 60.576 billion yuan [1]. - The net outflow of main funds was 237,700 yuan, while large orders showed a mixed trend with 9.09 million yuan in purchases and 10.61 million yuan in sales [1]. Business Overview - Haishike Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sales of chemical pharmaceuticals, with its main revenue sources being anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including Helicobacter pylori, hypertension treatment, and innovative drugs [1].